which was designed to evaluate MRK’s anti-PD-1 therapy Keytruda and the Japanese pharma giant’s tyrosine kinase inhibitor Lenvima for a certain type of cancer in the gastrointestinal tract.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback